Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769582 | 0.82 | HSD17B10 (0.40) | ESR1ESR2ERN1 | |
| SCHEMBL25317398 | 0.77 | ERN1 (0.64) | ERN1 | |
| SCHEMBL96645 | 0.73 | SELL (0.47) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL1098935 | 0.73 | CES2 (0.41) | CA12CA1 | |
| SCHEMBL833139 | 0.73 | ESR1 (0.56) | ESR1ESR2ERN1VRK1HSD17B1 | |
| SCHEMBL5511740 | 0.73 | CA9 (0.50) | ESR1ESR2ERN1VRK1HSD17B1 | |
| SCHEMBL27540052 | 0.71 | ERN1 (0.54) | ESR1ESR2ERN1VRK1MEP1B | |
| SCHEMBL3214111 | 0.69 | ERN1 (0.37) | ESR1ESR2ERN1VRK1 | |
| SCHEMBL1521849 | 0.69 | — | — | |
| SCHEMBL3698143 | 0.69 | CES2 (0.33) | ESR1ESR2ERN1VRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906556-B2 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | claimed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | claimed |
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1802574-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1305798-A2 | OPTICAL STORAGE USING MATERIALS COMPRISING CHROMOPHORE OLIGOMERS WHICH CAN UNDERGO CYCLOADDITION | Riso National Laboratory (DK) | 2003-05-02 | — | — | EP | claimed |
| EP-0828709-B1 | NOVEL PHYSICALLY FUNCTIONAL MATERIALS | OPTILINK AB (SE) | 2002-09-18 | — | — | EP | claimed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | claimed |
| US-20020025401-A1 | Optical storage using materials comprising chromophore oligomers which can undergo cycloaddition | OPTILINK AB (SE) | 2002-02-28 | — | — | US | claimed |
| WO-2001097217-A2 | OPTICAL STORAGE USING MATERIALS COMPRISING CHROMOPHORE OLIGOMERS WHICH CAN UNDERGO CYCLOADDITION | OPTILINK AB (SE) | 2001-12-20 | — | — | WO | claimed |
| EP-0828709-A1 | NOVEL PHYSICALLY FUNCTIONAL MATERIALS | FORSKNINGSCENTER RISO (DK) | 1998-03-18 | — | — | EP | claimed |
| WO-1996038410-A1 | NOVEL PHYSICALLY FUNCTIONAL MATERIALS | Forskningscenter Risø (DK) | 1996-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | ESR1 3282/4885ESR2 1536/4885ERN1 275/4885 |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | ESR1 4702/4885ESR2 3698/4885ERN1 818/4885 |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | AMY1A, AMY2A, DNPEP | ESR1 4604/4885ESR2 3616/4885ERN1 352/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | ESR1 3282/4885ESR2 1536/4885ERN1 275/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | ESR1 3735/4885ESR2 2624/4885ERN1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.